Fully Diluted: 46.2m
StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA
Monday November 5, 8:30 am ET
Scimitar Reserach Report
StatSure Diagnostic Systems, Inc.
(NASDAQ:SSUR; OTC: BB)
Earnings fully diluted
1st Quarter end March 31, 2007....... .02
2nd Quarter end June 30, 2007........ .01
6 months cummulated to June 30, 2007.. .03
Corporate Year end December 31, 2006..... (.15)
Quarter Report ending June 30, 2007
Quarter Report ending March 31, 2007 Form 10QSB
Annual Report Form 10KSB
StatSure Diagnostic Systems, Inc., (SDS)
, a Delaware corporation (the "Company"), is primarily engaged in the development and marketing of oral fluid collection devices for the drugs of abuse market, and rapid immunoassays for use in the detection of infectious diseases. The Company believes that its patented platform for rapid testing of infectious diseases offers significant advantages over the competition, including ease-of-use, lower costs, and significantly reduced risk of infection from collecting and handling specimens. In the oral fluid collection market, the Company's platform has a patented internal quality control that indicates sufficient volume of the oral fluid ("volume adequacy indicator"). On January 24, 2006, the Company effected a name change from Saliva Diagnostic Systems, Inc. to StatSure Diagnostic Systems, Inc. Since March 22, 2006, the shares of the Company have traded under the StatSure name, with the symbol SSUR. Coinciding with the corporate name change, the Company changed the name of its Hema-Strip HIV test to StatSure™ HIV.
Our business model calls for rapidly expanding our business. We feel the Inverness/Chembio agreement validated our barrel patent and the commercial potential of the technology platform. There is a broad menu of potential products that are candidates for development using the barrel assay format. They include hepatitis B and C, SARS, bird-flu, and others. The Company is currently seeking funds to use to target the development of one or more of these product opportunities.
While we are very excited about the potential of the base HIV business, we also want to leverage our technology platform to broaden this product base.